This novel method for content analysis, invented by Professor Ari Rappoport and Mr. Oren Tsur from the Hebrew University School of Computer Science and Engineering, is specifically designed to automatically rank book and product reviews according to their estimated helpfulness.
The compounds developed by Doron Steinberg, a professor in the Faculty of Dental Medicine, and Morris Srebnik, a professor in the Institute of Drug Research, and colleagues will be used to coat pipes, filters, membranes, air conditioning ducts, and other surfaces in contact with water that are prone to biofilm formation.
Read a book by light from power provided by your potato plants? That's the kind of dream Prof. Boris Rubinsky and his team think about and are at the initial stages of working on right now, along with Prof. Haim Rabinowitch, former Hebrew University rector, who invented the cherry tomato.
Under the agreement, BrightSource will fund research in the laboratories of Professors Daniel Mandler, and Shlomo Magdassi, both from the Institute of Chemistry at the Hebrew University of Jerusalem.
According to the terms of the agreement, Roche has selected six promising research projects in the fields of stem cells, biomarkers, and novel molecules for the treatment of metabolic diseases, initiated by Hebrew University researchers.
HUJI Professors Leonid Shvartsman and Boris Laikhtman have invented a novel design of TeraHertz-ray (T-ray) lasers with future applications for security cameras and spectrometers and medical imaging.
The Jerusalem Post: A new soundscape language has been created by an Israeli researcher that allows blind people to "see" objects, in much the same way a bat does.
The country's first interdisciplinary center for developing drugs will be opened this week by the Hebrew University of Jerusalem on the Ein Kerem campus of its School of Pharmacy - thereby utilizing the talents and ideas of a wide variety of campus scientists and attracting financial support from donors and the pharmaceutical industry.
Researchers at the Hebrew University and Shaarey Tzedek Hospital showed the effectiveness of using NewSit - a modification of a standard airline seat- to prevent DVT.
NewSit raises the feet from the floor, facilitates mobility, and permits intermittent calf compression.
A novel electrochemical approach for the formation of sol-gel based nanocomposite materials was developed by professors David Avnir and Daniel Mandler of the Institute of Chemistry at the Hebrew University of Jerusalem.
Biotech firm BioCancell Therapeutics Ltd. (TASE:BICL), which is developing drugs to fight cancer, said that its flagship drug BC-819 was granted orphan drug status for use against ovarian cancer. The move protects the drug from competition for at least seven years.
Research carried out at the laboratory of Prof. Hermona Soreq at The Hebrew University of Jerusalem has resulted in a promising approach to help treat Alzheimer’s disease in a significant proportion of the population that suffers from a particularly rapid development of this disease.
Following the debate on the allocation of public funding to the new Biotech Fund, Yissum CEO Yaacov Michlin explains the advantage of investing in biotechnology research.
Prof. Simon Benita's new drug delivery mechanism means that pharmaceutical developers can work around the intestinal pump, bypassing the gut enzyme metabolism, delivering maximum drug power without the side effects.
The technology was invented by a team led by Dan Gazit, a professor from the faculty of dental medicine. It includes a biologically compatible, oxygenated gel that improves
bone regeneration and fusion of bone grafts by increasing local oxygenation and fusion rates at the surgical site.
The collaboration is funded by the Israel-U.S. binational BIRD Foundation
HUJI Prof. Avraham Hochberg received this year’s first prize at the Kaye Innovations Awards during the annual Hebrew University Board of Governors meeting for his success in isolating the H19 gene in humans and determining that it is significantly expressed in over 33 different forms of cancer.
The agreement is the second delivery-technology deal in as many months for Yissum, which has been particularly successful at parlaying drug-delivery research conducted at Hebrew University into marketed products.
"I am personally committed to the field of biomed and the health and life sciences business cluster as a core competitive advantage that we must exploit in Jerusalem," Barkat said at a reception hosted by the Yissum Research Development Company of the Hebrew University at the three-day Tel Aviv ILSI Biomed Israel 2009 conference.
This new invention will be presented at the Tel Aviv Biomed 2009 conference, June 15-17.